Sinopharm Group Co Ltd
HKEX:1099

Watchlist Manager
Sinopharm Group Co Ltd Logo
Sinopharm Group Co Ltd
HKEX:1099
Watchlist
Price: 20.6 HKD -1.67%
Market Cap: 64.3B HKD
Have any thoughts about
Sinopharm Group Co Ltd?
Write Note

Operating Margin
Sinopharm Group Co Ltd

3.5%
Current
4%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.5%
=
Operating Profit
20.8B
/
Revenue
590.3B

Operating Margin Across Competitors

Country CN
Market Cap 65.4B HKD
Operating Margin
4%
Country US
Market Cap 77.7B USD
Operating Margin
1%
Country US
Market Cap 48.9B USD
Operating Margin
1%
Country US
Market Cap 48.4B USD
Operating Margin
1%
Country US
Market Cap 30.1B USD
Operating Margin
1%
Country US
Market Cap 9.3B USD
Operating Margin
5%
Country CN
Market Cap 65B CNY
Operating Margin
10%
Country KR
Market Cap 12.2T KRW
Operating Margin
9%
Country CN
Market Cap 60.9B CNY
Operating Margin
3%
Country IT
Market Cap 5.5B EUR
Operating Margin
12%
Country DE
Market Cap 5B EUR
Operating Margin
1%
No Stocks Found

Sinopharm Group Co Ltd
Glance View

Market Cap
64.3B HKD
Industry
Health Care

Sinopharm Group Co., Ltd. stands as a formidable player in the global healthcare landscape, rooted in its status as China's largest distributor of pharmaceuticals and healthcare products. Established in 1998 and publicly traded since 2003, the company plays a central role in the life sciences sector, producing not only a diverse range of medicines and vaccines but also engaging in extensive logistics and supply chain management that ensures healthcare products reach every corner of the vast Chinese market. This comprehensive approach to healthcare distribution is complemented by its robust R&D initiatives, which are driving innovations across multiple therapeutic areas. Notably, Sinopharm became internationally recognized for its key role in the production and distribution of COVID-19 vaccines, further solidifying its prominence in the industry and widening its investor appeal amid a heightened focus on public health. As an investor, Sinopharm’s strategic positioning in the healthcare ecosystem presents a compelling opportunity for long-term growth. With a strong emphasis on integrating technology within its operations, the company aims to enhance operational efficiencies and improve patient outcomes. Additionally, its ongoing expansion into international markets positions Sinopharm not only to capitalize on China's booming healthcare sector but also to tap into the global demand for high-quality medical products. Backed by a solid financial performance and favorable government policies, investors can view Sinopharm as a potential cornerstone in a diversified portfolio, blending stability with the prospects of future innovation and expansion.

Intrinsic Value
92.8 HKD
Undervaluation 78%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.5%
=
Operating Profit
20.8B
/
Revenue
590.3B
What is the Operating Margin of Sinopharm Group Co Ltd?

Based on Sinopharm Group Co Ltd's most recent financial statements, the company has Operating Margin of 3.5%.